$116.98 -4.39 (%) Alnylam Pharmaceuticals Inc - NASDAQ

Apr. 17, 2015 | 04:00 PM

Partner Headlines

  1. It's A Big Weekend For Biotech

    Benzinga | Apr. 17, 2015 | 16:31PM EST
  2. Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3

    Benzinga | Apr. 13, 2015 | 11:01AM EST
  3. Benzinga's Top Initiations

    Benzinga | Feb. 27, 2015 | 09:29AM EST
  4. Microsoft, Bank Of New York And Others Insiders Have Been Buying

    Benzinga | Feb. 2, 2015 | 08:57AM EST
  5. Deutsche Bank's Top Biotech Picks For 2015

    Benzinga | Jan. 22, 2015 | 11:09AM EST
  6. Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following Equity Offering; Insperity Shares Spike Higher

    Benzinga | Jan. 21, 2015 | 15:10PM EST
  7. 4 More Biotech Secondaries Traders Are Watching

    Benzinga | Jan. 21, 2015 | 13:38PM EST
  8. Mid-Day Market Update: U.S. Stocks Surge; Netflix Shares Jump On Upbeat Earnings

    Benzinga | Jan. 21, 2015 | 12:53PM EST
  9. Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit Tops Expectations

    Benzinga | Jan. 21, 2015 | 10:42AM EST
  10. Shares Of Alnylam Pharmaceuticals Lower Following Equity Offering

    Benzinga | Jan. 21, 2015 | 10:03AM EST
  11. Morning Market Losers

    Benzinga | Jan. 21, 2015 | 09:55AM EST
  12. Wednesday Morning Movers: Netflix Flying High

    Benzinga | Jan. 21, 2015 | 08:55AM EST
  13. Alnylam Pharmaceuticals

    IBD | Jan. 20, 2015 | 18:44PM EST
  14. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  15. Alnylam Files Clinical Trial Application to Initiate a Phase 1 Study for ALN-AS1, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias

    Benzinga | Jan. 5, 2015 | 08:02AM EST
  16. Mid-Day Market Update: McDonald's Drops On Weak November Sales; Acceleron Pharma Shares Jump

    Benzinga | Dec. 8, 2014 | 12:56PM EST
  17. Mid-Morning Market Update: Markets Mixed; Merck To Buy Cubist Pharmaceuticals For $102/Share

    Benzinga | Dec. 8, 2014 | 10:46AM EST
  18. Alnylam jumps on trial results

    IBD | Oct. 13, 2014 | 18:46PM EST
  19. U.S. Stocks Fluctuate; Shutterfly Shares Decline On Aborted Merger Talks

    Benzinga | Oct. 13, 2014 | 15:18PM EST
  20. Alnylam Drug Scores Against Rare Nerve Disease

    IBD | Oct. 13, 2014 | 13:59PM EST
  21. Midday Gainers From October 13 - Doral Financial, Nanosphere, Ibio, Atlas Energy

    Benzinga | Oct. 13, 2014 | 13:55PM EST
  22. Lithia Motors Dips On Lowered Earnings Forecast; CSX Shares Gain

    Benzinga | Oct. 13, 2014 | 12:30PM EST
  23. Markets Down; Targa To Acquire Atlas Pipeline, Atlas Energy

    Benzinga | Oct. 13, 2014 | 11:05AM EST
  24. Benzinga's Volume Movers

    Benzinga | Oct. 13, 2014 | 10:12AM EST
  25. Morning Market Movers

    Benzinga | Oct. 13, 2014 | 09:39AM EST
  26. Alnylam Broadens Pipeline With ALN-AGT, A Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen For The Treatment Of Hypertensive Disorders Of Pregnancy, Including Preeclampsia

    Benzinga | Sep. 12, 2014 | 08:02AM EST
  27. The Biotech Stock With The Biggest Head Of Steam

    Benzinga | Aug. 4, 2014 | 14:35PM EST
  28. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD | Jun. 30, 2014 | 17:00PM EST
  29. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga | Jun. 23, 2014 | 18:25PM EST
  30. Alnylam Pharma

    IBD | May. 12, 2014 | 18:42PM EST
  31. Alnylam Presents Pre-Clinical Data on RNAi Therapeutics at ISA

    Benzinga | Apr. 29, 2014 | 08:02AM EST
  32. UPDATE: Alnylam, Collaborators to Offer New Clinical Data for Patisiran

    Benzinga | Apr. 28, 2014 | 08:02AM EST
  33. UPDATE: Alnylam Receives Positive Opinion for Orphan Drug Designation in EU for ALN-TTRsc

    Benzinga | Apr. 2, 2014 | 08:05AM EST
  34. Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)

    Benzinga | Jan. 22, 2014 | 08:03AM EST
  35. UPDATE: Morgan Stanley Downgrades Alnylam Pharmaceuticals, Sees Robust Drug Prospects

    Benzinga | Jan. 14, 2014 | 10:53AM EST
  36. Benzinga's M&A Chatter for Monday January 13, 2014

    Benzinga | Jan. 13, 2014 | 18:05PM EST
  37. Market Wrap For January 13: Markets Showing Weakness Ahead Of Major Earning Releases

    Benzinga | Jan. 13, 2014 | 16:52PM EST
  38. Mid-Afternoon Market Update: Markets Dip Despite Large Amount of M&A

    Benzinga | Jan. 13, 2014 | 16:14PM EST
  39. Mid-Day Market Update: SodaStream Drops After Weak Outlook; Beam Shares Spike Higher

    Benzinga | Jan. 13, 2014 | 12:52PM EST
  40. Mid-Morning Market Update: Markets Open Lower; Lululemon Lowers Q4 Outlook

    Benzinga | Jan. 13, 2014 | 10:39AM EST
  41. UPDATE: JMP Securities Reiterates Market Perform on Alnylam Pharmaceuticals on Therapeutic Candidates

    Benzinga | Jan. 13, 2014 | 10:32AM EST
  42. Morning Market Movers

    Benzinga | Jan. 13, 2014 | 09:54AM EST
  43. Stocks Futures Mildly Lower; Lululemon, Ascena Pare Guidance

    IBD | Jan. 13, 2014 | 09:00AM EST
  44. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 13, 2014 | 08:21AM EST
  45. US Stock Futures Fall Ahead Of Federal Budget

    Benzinga | Jan. 13, 2014 | 06:41AM EST
  46. Genzyme, Alnylam Expand Collaboration on Rare Genetic Diseases

    Benzinga | Jan. 13, 2014 | 05:54AM EST
  47. Alnylam Acquires Sirna Therapeutics from Merck for $175M Upfront Payment in Cash, Stock

    Benzinga | Jan. 13, 2014 | 05:53AM EST
  48. Tekmira Receives $5M Milestone Payment from Alnylam

    Benzinga | Dec. 16, 2013 | 20:02PM EST
  49. Alnylam Presents New Pre-clinical Data on ALN-AT3 for Treatment of Hemophilia and RBD at ASH

    Benzinga | Dec. 9, 2013 | 20:59PM EST
  50. Alnylam Earns $7M Milestone Payment from Partner Genzyme for Phase II Success with Patisiran

    Benzinga | Nov. 25, 2013 | 07:02AM EST
Trading Center